Recent Industry Update

• Pfizer to acquire Biohaven Pharma for $11.6 billion
• EMA recommendation for 2022-2023 seasonal flu vaccine composition
• Aurobindo Pharma acquires Veritaz Healthcare
• Sun Pharma to launch Vortioxetine in India
• what is meaning of clinically significant endpoint?
• US FDA grants Breakthrough Therapy Designation for Pfizer’s RSVpreF
• Is HEOR and Market Access is same?
• Symbicort 1st generic Approval by USFDA
• Case Study : Vimpat patent expired on 17th of March, 2022 and generic entry
• Case Study : US FDA approval of Marinus Pharma’s Ztalmy
• Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China
• What if Design of experiments (DoE) approach?
• Torrent Pharma to manufacture and sell Pfizer’s Paxlovid generic
• What are the application of IVIVC?
• What is the meaning of IVIVC?
• Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative
• Medtronic launched MiniMed 780G system to manage type 1 diabetes
• Case Study: Pfizer’s Arena acquisition – A $6.7B deal
• Market Access – Check your competency
• Zydus gets orphan drug designation from USFDA for antimalarial compound
• Keros Therapeutics Strategic deal with Hansoh Pharma for Rights to KER-050 in China
• Case Study: Acquisition of Otrexup – A Drug Device Combination
• Case Insight: Natco acquires Dash Pharmaceuticals
• Cadila launches ayurvedic energy tonic Healtherbs
• Cipla’s social initiative to improve access to nebulisers in primary healthcare centres of rural India
• Aqilion buys rights to Phase-I ready anti-inflammatory program from LEO Pharma
• SPARC entered into a licensing agreement with Biomodifying
• AbbVie’s Skyrizifor received EC approval to treat adults with active psoriatic arthritis
• Insight on licensing deal of Pfizer and The Medicines Patent Pool for COVID-19 Oral Antiviral Treatment Candidate to Expand market Access in Low- and Middle-Income Countries
• Pharma Case Study: Merck’s $11.5B acquisition of Acceleron